Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention
Cells · 04.11.2024 · 13 (21) · 1819
DOI: 10.3390/cells13211819 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, online erschienen am 04.11.2024. Verfasst von Peng He und 4 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Stem Cell Regulation and Application of Traditional Chinese Medicine, School of Pharmacy, Hunan University of Chinese Medicine, Changsh…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Hyaluronic Acid, Liver Neoplasms, Pentacyclic Triterpenes. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Key guidance topics of Hunan Provincial Health Commission, Hunan Provincial Natural Science Foundation Youth Project.
Abstract (Originalsprache)
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related deaths worldwide, and its prevention and treatment face severe challenges. It is crucial to improve the targeting of drugs on tumor cells and tissues. Celastrol (CeT), as an active ingredient of traditional Chinese medicine, possesses strong antitumor effects, especially in triggering apoptosis of HCC. However, due to its toxicity and lack of targeting, its application is greatly limited. HMCLPs, a nano-biomimetic platform carrying CeT with controllable drug release, enhanced targeting, and immunocompatibility, were developed for the first time, which can be used for the treatment of HCC. By utilizing homologous cell membranes and hyaluronic acid (HA), HMCLPs can precisely target tumor regions and release CeT in a controlled manner. Both in vitro and in vivo studies have demonstrated that HMCLPs loaded with CeT significantly increased the accumulation of reactive oxygen species (ROS), induced mitochondrial damage, and triggered apoptosis of HCC cells, resulting in effective treatment with minimal adverse reaction. The development of HMCLPs as a nanocarrier system for CeT delivery offers a promising therapeutic strategy for HCC. This innovative approach improves the targeted delivery and bioavailability of CeT, dramatically induces apoptosis in HCC cells, and exerts its powerful antitumor effects while minimizing systemic toxicity. The present study highlights the potential of combining innovative nanocarriers with powerful natural compounds such as CeT to enhance efficacy and reduce toxicity.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Stem Cell Regulation and Application of Traditional Chinese Medicine, School of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
- Science and Technology Innovation Center, Hunan University of Chinese Medicine, Changsha 410208, China.
ORCID-Profile: Li Qin
Förderung
- National Natural Science Foundation of China
- Key guidance topics of Hunan Provincial Health Commission
- Hunan Provincial Natural Science Foundation Youth Project
- Hunan Provincial Education Department Outstanding Youth Project
- Postgraduate Innovation project of Hunan University of Chinese Medicine
Zitieren
APA
He, P., Zou, M., Zhang, C., Shi, Y., & Qin, L. (2024). Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention. Cells, 13(21), 1819. https://doi.org/10.3390/cells13211819
Vancouver
He P, Zou M, Zhang C, Shi Y, Qin L. Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention. Cells. 2024;13(21):1819. doi:10.3390/cells13211819
BibTeX
@article{He2024,
author = {He, Peng and Zou, Manshu and Zhang, Chanjuan and Shi, Yaning and Qin, Li},
title = {Celastrol-Loaded Hyaluronic Acid/Cancer Cell Membrane Lipid Nanoparticles for Targeted Hepatocellular Carcinoma Prevention},
journal = {Cells},
year = {2024},
volume = {13},
number = {21},
pages = {1819},
doi = {10.3390/cells13211819}
}
EUVIMED